January 10, 2021
Greffex, a pioneering vaccine and gene therapy company with a lab in Aurora, Colorado and headquartered in Houston, Texas began pre-clinical trials this week on its Covid-19 monovalent vaccine.
This is the first step in Greffex’s Covid-19 pre-clinical trials which will subsequently involve trials for its bi-valent and tri-valent Covid-19 vaccine candidates. Greffex’s Covid-19 vaccine will come in a single dose, will not require a freezer for storage, and will be multi-valent by presenting the Spike, M and N proteins or some combination, making for a more durable vaccine better equipped to handle mutations.
Core to the Greffex vaccine platform is its patented fully-deleted helper independent adenoviral vector technology which improves upon early generation Ad vectors. In addition, Greffex will base its vaccine on the rare human serotype Ad6. Taken together, these scientific advancements should translate to cleaner, safer, more effective and durable vaccines.